Christian Brühlmann
Corporate Officer/Principal bij ONCONETIX, INC.
Vermogen: 48 622 $ op 31-05-2024
Profiel
Christian Brühlmann is the founder and the Chief Business Officer of Proteomedix AG, a company founded in 2010.
He is currently the Chief Strategy Officer at Onconetix, Inc., starting in 2023.
Mr. Brühlmann has a graduate degree from the University of Zurich.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ONCONETIX INC
1.06% | 05-04-2024 | 236 029 ( 1.06% ) | 48 622 $ | 31-05-2024 |
Actieve functies van Christian Brühlmann
| Bedrijven | Functie | Begin |
|---|---|---|
| ONCONETIX, INC. | Corporate Officer/Principal | 01-12-2023 |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Oprichter | 01-01-2010 |
Opleiding van Christian Brühlmann
| University of Zurich | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ONCONETIX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
